sub:assertion {
  d:DB05773 v:identifier "DB05773" ;
    v:namespace "drugbank" ;
    v:uri "http://bio2rdf.org/drugbank:DB05773" ;
    v:x-identifiers.org <http://identifiers.org/drugbank/DB05773> ;
    dv:drugbank-id "DB05773" ;
    dv:x-cas <http://bio2rdf.org/cas:1018448-65-1> ;
    dv:x-kegg <http://bio2rdf.org/kegg:D09980> ;
    dv:x-ndc <http://bio2rdf.org/ndc:50242-087-01> ;
    dv:x-wikipedia <http://bio2rdf.org/wikipedia:Trastuzumab_emtansine> ;
    dct:description "Ado-trastuzumab emtansine, formerly called Trastuzumab-DM1 (T-DM1) as an investigational drug, is a first-in-class HER2 antibody drug conjugate (ADC) comprised of Genentech's trastuzumab antibody linked to ImmunoGen's cell-killing agent, DM1. T-DM1 combines two strategies-- anti-HER2 activity and targeted intracellular delivery of the potent anti-microtubule agent, DM1 (a maytansine derivative)--to produce cell cycle arrest and apoptosis. Ado-trastuzumab emtansine is marketed under the brand name Kadcyla and is indicated for use in HER2-positive, metastatic breast cancer patients who have already used taxane and/or trastuzumab for metastatic disease or had their cancer recur within 6 months of adjuvant treatment. The FDA label has two precautions. First that ado-trastuzumab emtansine and trastuzumab cannot be interchanged. Second that there is a black box warning of serious side effects such as hepatotoxicity, embryo-fetal toxicity, and cardiac toxicity."@en ;
    dct:identifier "drugbank:DB05773" ;
    dct:title "ado-trastuzumab emtansine"@en ;
    a dv:Drug ;
    rdfs:label "ado-trastuzumab emtansine [drugbank:DB05773]"@en ;
    rdfs:seeAlso <http://www.drugbank.ca/drugs/DB05773> , <http://www.drugs.com/mtm/ado-trastuzumab-emtansine.html> , <http://www.rxlist.com/kadcyla-drug.htm> .
}